¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : ºÐÀÚº°, ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule, By Application, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1588383
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 140 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 55¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 10.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á ºóµµ Áõ°¡, ±ÔÁ¦ °æ·ÎÀÇ °£¼ÒÈ­, Á¦³×¸¯ ÀǾàǰÀÇ Àúºñ¿ëÈ­, Á¦³×¸¯ ÁÖ»çÁ¦ ºÐ¾ß¿¡¼­ CDMOÀÇ º¸±Þ È®´ëÀÔ´Ï´Ù.

Äڷγª19 ÆÒµ¥¹ÍÀº ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ºÎ¹®À» Æ÷ÇÔÇÑ °ø±Þ¸Á ½ÃÀå°ú ±× °ü¸®¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. »õ·Î¿î Á¦³×¸¯ ÁÖ»çÁ¦ÀÇ ÀÓ»ó½ÃÇè ½Ç½Ã´Â Àü¿°º´°ú °ü·ÃµÈ ¾ÈÀü ¿ì·Á ¹× Á¦ÇÑÀ¸·Î ÀÎÇØ º¯°æµÇ°Å³ª ¿¬±âµÇ¾î °³¹ß ÀÏÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ Á¦¾àȸ»ç°¡ Äڷγª19 ¹é½Å »ý»ê¿¡ »ý»ê´É·ÂÀ» ÅõÀÔÇϸ鼭 Á¦³×¸¯ ÁÖ»çÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¸¥ ÀǾàǰÀÇ »ý»ê ÀÏÁ¤°ú »ý»ê´É·Â¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ÁÖ»çÁ¦ÀÇ Æ¯Çã°¡ ¸¸·áµÇ´Â ÁÖ»çÁ¦ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¹Ì±¹ Á¦³×¸¯ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ FDA¿¡ µû¸£¸é Å©·Ðº´, °üÀý¿°, ½É»ó¼º °Ç¼±, °­Á÷¼º ôÃß¿°À» Ä¡·áÇÏ´Â ¾Öºêºñ(AbbVie)ÀÇ È÷Æ® ÁÖ»çÁ¦ È޹̶ó(Humira)´Â 2023³â ƯÇã°¡ ¸¸·áµË´Ï´Ù. ƯÇã ¸¸·á·Î ÀÎÇØ ¾Æ´Þ¸®¹«¸¿ÀÇ Á¦³×¸¯ ÀǾàǰ µµÀÔÀÇ ±æÀÌ ¿­·È½À´Ï´Ù. ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀå¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå : ºÐÀÚ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Growth & Trends:

The U.S. generic injectables pharmaceutical contract manufacturing market size is expected to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The U.S. market is expected to expand at a CAGR of 10.8% from 2025 to 2030. Key factors driving the growth of this market are the rising frequency of patent expirations for blockbuster drugs, streamlined regulatory pathways, low cost of generics, and increasing penetration of CDMOs in the generic injectables space.

The COVID-19 pandemic significantly impacted the supply chain market and its management, including the U.S. generic injectables pharmaceutical contract manufacturing sector. The conduction of clinical trials for new generic injectables has been modified or delayed due to pandemic-related safety concerns and restrictions, potentially impacting the development timeline. Furthermore, several pharmaceutical companies pivoted their production capacities to manufacture COVID-19 vaccines, significantly impacting the production timelines and capacity for other pharmaceuticals, including generic injectables.

The increasing number of patent expirations for biologic injectables is a key factor contributing to the growth of the generic injectables market in the country. For instance, as per the U.S. FDA, the blockbuster injectable drug Humira, developed by AbbVie Inc. that treats the symptoms of Crohn's disease, arthritis, plaque psoriasis, and Ankylosing Spondylitis, has lost its patent in 2023. This expiration has paved the way for introducing its generic counterpart, adalimumab. The rising demand for generics owing to their cost-effectiveness is another significant factor contributing to the growth of the U.S. market for generic injectables pharmaceutical contract manufacturing.

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Report Highlights:

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope

Chapter 4. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Molecule Estimates & Trend Analysis

Chapter 5. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis

Chapter 6. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â